Clinical Scorecard: Natural and Synthetic Agents Enhance Autophagic Activity to Mitigate Doxorubicin-Induced Cardiomyopathy
At a Glance
Category
Detail
Condition
Doxorubicin-induced cardiomyopathy
Key Mechanisms
Impairment of autophagic flux leading to myocardial toxicity; restoration of autophagy reduces cardiac injury
Target Population
Cancer patients receiving doxorubicin chemotherapy
Care Setting
Oncology and cardiology clinical settings with potential translational applications
Key Highlights
Doxorubicin causes dose-dependent cardiomyopathy affecting ~30% of patients within 5 years.
Autophagy impairment is a key mechanism in doxorubicin-induced cardiac damage.
Natural (trehalose, spermidine) and synthetic (Tat-Beclin 1 D11) autophagy activators mitigate cardiac dysfunction without interfering with doxorubicin's antitumor effects.
Guideline-Based Recommendations
Diagnosis
Monitor cardiac function in patients receiving doxorubicin using echocardiography including fractional shortening, ejection fraction, and global longitudinal strain.
Management
Consider pharmacological activation of autophagy using agents such as trehalose, spermidine, or Tat-Beclin 1 D11 to reduce doxorubicin-induced cardiotoxicity.
Administer trehalose orally and intraperitoneally or spermidine orally as dietary supplements with negligible side effects.
Monitoring & Follow-up
Regular echocardiographic assessment post-chemotherapy to evaluate cardiac structure and function.
Post-treatment evaluation of autophagy markers, fibrosis, apoptosis, and mitochondrial integrity in research or specialized settings.
Risks
Doxorubicin cardiotoxicity is dose-dependent and may lead to progressive cardiomyopathy.
Autophagy activators used (trehalose, spermidine) have negligible side effects and do not interfere with doxorubicin's antitumor efficacy.
Patient & Prescribing Data
Mice models mimicking human doxorubicin-induced cardiomyopathy and breast cancer
Trehalose (2% in water plus i.p. injections), spermidine (3 mM in water), and Tat-Beclin 1 D11 (15 mg/kg i.p. thrice weekly) improved cardiac function and mitochondrial health without reducing doxorubicin's anticancer activity.
Clinical Best Practices
Use echocardiography including global longitudinal strain for sensitive detection of cardiac dysfunction.
Employ autophagy activators as adjunctive therapy to mitigate cardiotoxicity in patients undergoing anthracycline chemotherapy.
Ensure experimental treatments do not compromise chemotherapeutic efficacy by monitoring tumor growth in relevant models.
